|
|
|
|
|
Methyprylon
drug data and news
Methyprylon drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Methyprylon | ||
| Brand Names/Synonyms | CHEMBANK4389; Dea No. 2575; Dimerin; HSDB 3128; Maleate; Methprylon; Methyprolon; Methyprylon; Methyprylon [Inn]; Methyprylone; Methyprylone [Inn-French]; Methyprylonum [Inn-Latin]; Metiprilon; Metiprilona [Inn-Spanish]; Metiprilone; Noctan; Nodular; Noludar | ||
| Indication | For the treatment of insomnia | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Methyprylon, a piperidinedione CNS depressant, is close to barbituric acid in structure, but different enough to be called a "non-barbiturate" sedative-hynotic. Methyprylon is used for insomnia and daytime tension. Methyprylon depresses the activity of muscle tissues, the heart, and the respiratory system. | ||
| Mechanism Of Action | Methyprylon binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. | ||
| Methyprylon News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Sedatives and Hypnotics; ATC:N05CE02 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Methyprylon: Methyprylon may interact with other addictive medications, in that it may increase the likelyhood of addiction and abuse. Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications. | ||
| Toxicity | Symptoms of overdose include excitation and convulsions. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 3,3-diethyl-5-methyl-piperidine-2,4-dione | ||
| Chemical Formula | C10H17NO2 | ||
| Molecular Weight | 183.248 g/mol | ||
| Smiles String | CCC1(C(=O)C(CNC1=O)C)CC | ||
| Melting Point | Not Available | ||
| Water Solubility | 1.15E+004 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 1.639 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. Methyprylon is almost completely metabolized. | ||
| Half Life | 6-16 hours | ||
| Protein Binding [%] | 60% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Methyprylon.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00734 | ||
| CAS Registry Number | 125-64-4 | ||
| KEGG Compound ID | C12550 | ||
| PubChem ID | SID:582940 | ||
| PharmGKB ID | PA450470 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |